Leukodystrophies
- PMID: 29432240
- DOI: 10.1212/CON.0000000000000560
Leukodystrophies
Abstract
Purpose of review: The leukodystrophies, typically considered incurable neurodegenerative disorders, are often diagnosed after irreversible central and peripheral nervous system injury has occurred. Early recognition of these disorders is imperative to enable potential therapeutic interventions. This article provides a summary of the symptoms of and diagnostic evaluation for leukodystrophies, along with the currently available therapies and recent advances in management.
Recent findings: The leukodystrophies are a rapidly expanding field because of advances in neuroimaging and genetics; however, recognition of the clinical and biochemical features of a leukodystrophy is essential to accurately interpret an abnormal MRI or genetic result. Moreover, the initial symptoms of leukodystrophies may mimic other common pediatric disorders, leading to a delay in the recognition of a degenerative disorder.
Summary: This article will aid the clinician in recognizing the clinical features of leukodystrophies and providing accurate diagnosis and management.
Similar articles
-
Leukodystrophies with late disease onset: an update.Curr Opin Neurol. 2010 Jun;23(3):234-41. doi: 10.1097/WCO.0b013e328338313a. Curr Opin Neurol. 2010. PMID: 20216214 Review.
-
Leukodystrophies.Continuum (Minneap Minn). 2022 Aug 1;28(4):1194-1216. doi: 10.1212/CON.0000000000001130. Continuum (Minneap Minn). 2022. PMID: 35938662 Free PMC article. Review.
-
Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment.Curr Opin Neurol. 2001 Jun;14(3):305-12. doi: 10.1097/00019052-200106000-00007. Curr Opin Neurol. 2001. PMID: 11371752 Review.
-
Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.Curr Neurol Neurosci Rep. 2005 Mar;5(2):110-8. doi: 10.1007/s11910-005-0008-1. Curr Neurol Neurosci Rep. 2005. PMID: 15743548 Review.
-
Leukodystrophies: classification, diagnosis, and treatment.Neurologist. 2009 Nov;15(6):319-28. doi: 10.1097/NRL.0b013e3181b287c8. Neurologist. 2009. PMID: 19901710 Review.
Cited by
-
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.Cancers (Basel). 2022 Jan 29;14(3):687. doi: 10.3390/cancers14030687. Cancers (Basel). 2022. PMID: 35158955 Free PMC article. Review.
-
Neurogenic Bladder and Acute Kidney Injury in Leukodystrophy.Cureus. 2020 Jun 20;12(6):e8707. doi: 10.7759/cureus.8707. Cureus. 2020. PMID: 32699703 Free PMC article.
-
Inhibitors of Myelination and Remyelination, Bone Morphogenetic Proteins, are Upregulated in Human Neurological Disease.Neurochem Res. 2020 Mar;45(3):656-662. doi: 10.1007/s11064-020-02980-w. Epub 2020 Feb 6. Neurochem Res. 2020. PMID: 32030597 Free PMC article. Review.
-
Emerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies.Front Cell Neurosci. 2021 Jun 22;15:661857. doi: 10.3389/fncel.2021.661857. eCollection 2021. Front Cell Neurosci. 2021. PMID: 34239416 Free PMC article. Review.
-
Leukodystrophy Imaging: Insights for Diagnostic Dilemmas.Med Sci (Basel). 2024 Jan 25;12(1):7. doi: 10.3390/medsci12010007. Med Sci (Basel). 2024. PMID: 38390857 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials